



69/16179  
PATENT  
TECH CENTER 1600/2900  
JUN 05 2002  
RECEIVED  
TECH CENTER 1600/2900  
JUN 06 2002  
RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Jeffry Weers et al. ) Atty Docket No.: 0103.00  
Application No. 09/888,311 )  
Filed: 6/22/2001 ) Examiner: K. Stiller  
Title: PHOSPHOLIPID-BASED POWDERS ) Group Art Unit: 1617  
FOR INHALATION ) May 20, 2002

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on May 21, 2002

Signed: Kathy Horneit

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §1.56, §1.97 and §1.98**

Commissioner for Patents  
Washington, DC 20231

Dear Sir:

The references listed in the attached Form PTO/SB/08A,B may be material to examination of the above-identified patent application. Applicants submit these references in compliance with their duty of disclosure pursuant to 37 CFR §§1.56, 1.97, and 1.98. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these references indeed constitute prior art.

Copies of the references are enclosed, as required under 37 CFR §§1.98. The references on the attached Form PTO/SB/08A,B identified by an asterisk (\*) were previously cited by or submitted to the PTO in a prior application relied upon for an earlier filing date. Accordingly, in compliance with 37 CFR §§1.98 (d), copies of these references have not been provided.

06/05/2002 NM0HAMM1 00000132 500348 09888311

01 FC:126

180.00 CH

Attorney Docket No. 0103.00

This Information Disclosure Statement is being timely filed under 37 CFR §§1.97 and is being filed:



- within three months of the filing date of a national application; within three months of the date of entry of the national stage as set forth in section 1.491 in an international application; or before the mailing date of a first Office action on the merits (whichever event occurs last);
- more than three months from the filing date of an application and after the mailing date of a first Office action on the merits, but before the mailing date of either a final action under section 1.113 or a notice of allowance under section 1.311 (whichever occurs first), and is accompanied by:
  - the fee set forth in 37 CFR 1.17(p) for submission of an information disclosure statement under §1.97(c) (\$180.00); or
  - one of the following statements as specified in 37 CFR 1.97(e) that:
    - each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or
    - no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in section 1.56(c) more than three months prior to the filing of the information disclosure statement; or
- after the mailing date of either a final action under section 1.113 or a notice of allowance under section 1.311, but on or before the payment of the issue fee, and is accompanied by each of:
  - the following petition:

Applicant hereby requests consideration of the accompanying information disclosure statement;
  - the petition fee set forth in 37 CFR 1.17(i) (\$130.00); and
  - one of the following statements as specified in 37 CFR 1.97(e) that:
    - each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three



months prior to the filing of the information disclosure statement; or

no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in section 1.56(c) more than three months prior to the filing of the information disclosure statement.

Each item of information contained within this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement. Accordingly, this Information Disclosure Statement does not constitute a failure on the part of the Applicant to engage in reasonable efforts to conclude prosecution of the application as set forth in 37 CFR 1.704 "Reduction of period of adjustment of patent term."

Attached is Check No.   in the amount of \$0.

Please charge the amount of \$ 180.00 to Deposit Account 500348


If it is determined that any additional fees are due, the Commissioner is hereby authorized to charge such fees to Deposit Account 50-0348.

Respectfully submitted,

INHALE THERAPEUTIC SYSTEMS, INC.

Dated: 5/21/02

By:

  
\_\_\_\_\_  
Michael J. Rafa  
Reg. No. 38,740

San Carlos, CA 94070  
(650) 631-3100

RECEIVED  
JUN 06 2002  
TECH CENTER 1800  
JUN 06 2002  
1800/2900